[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-urinary-retention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-urinary-retention":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,81,103,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100649472","phase-2-study-of-teverelix-dp-on-prostate-volume-urinary-function-and-clinical-outcomes-following-acute-urinary-retention-100649472",false,"NCT07733934","Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention","A Randomized, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Effects of Teverelix DP, a GnRH Antagonist, on Prostate Volume, Urinary Function and Clinical Outcomes in Men Following a First Episode of Acute Urinary Retention (AUR)","Inclusion Criteria:\n\n1. Male aged 45 years or older\n2. Having given his written consent\n3. Successful TWOC as defined by successful voiding with a minimum residual volume\n4. Having had a first episode of spontaneous acute urinary retention within 6 days of study screening visit.\n5. Prostate volume \\>40 g (assessed by TRUS)\n6. Patients may initiate or continue alpha-blocker therapy at or before randomization. The same agent and dose should be continued throughout the treatment period where possible\n7. Agrees to practice contraception during the entire study treatment period and for 3 months after the last dose of IMP is administered:\n\n   1. Either by using double barrier contraception and in compliance with local guidelines,\n   2. or, is truly sexually abstinent, when this is in line with the preferred and usual lifestyle of the patient\n\n   i. Note: Periodic abstinence \\[e.g. calendar, ovulation, symptothermal, postovulation methods for the female partner with childbearing potential\\] and withdrawal are not acceptable methods of contraception.\n8. Must be treatment naïve to GnRH analogues\n\nExclusion Criteria:\n\n1. Participated in another investigational study within 3 months before recruitment\n2. AUR due to i.e. postoperative retention following major abdominal\u002Fpelvis\u002Fspinal surgery\n3. Neurological related AUR\n4. Contraindication to the use of alpha blockers\n5. Previous prostate or urethral surgery\n6. Previous histological or clinical diagnosis of prostate cancer\n7. Any unstable co-existing medical condition\n8. Has abnormal screening and\u002For baseline laboratory values that suggest a clinically significant underlying disease, or the following laboratory values:\n\n   1. Liver function test (aspartate aminotransferase \\[ASAT\u002FSGOT\\], alanine aminotransferase \\[ALAT\u002FSGPT\\]), exceeding \\>2X the upper limit of the normal (ULN) range\n   2. Total bilirubin exceeding \\>1.5X the upper limit of the normal (ULN) range\n   3. An estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin, based on creatinine clearance calculation by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation normalised to an average surface area of 1.73m2, at the screening visit.\n9. Has congenital long QT syndrome or ECG abnormalities at screening of:\n\n   1. Q-wave infarction, unless identified ≥6 months before screening\n   2. Fridericia corrected QT interval (QTcF interval) \\>480 msec. If QTcF is prolonged in a patient with a pacemaker, the patient may be enrolled in the study upon discussion with the project clinician\n   3. If the QTcF interval is 450-480 msec, inclusive, in a patient with current use of medications with known effects on QT interval, the patient may be enrolled in the study following discussion with the Medical Lead\n\n   Note: Cardiac arrhythmia grading:\n   * Bradyarrhythmias (HR \\\u003C60\u002Fmin)\n   * Tachyarrhythmias (HR \\>100\u002Fmin\n   * Supraventricular arrhythmias - arrhythmias that originate in the sinoatrial node, atrial myocardium or atrioventricular node (regular QRS complex)\n   * Ventricular arrhythmias - arrhythmias that originate below the atrioventricular node (wide QRS complex)\n10. History or current evidence of alcohol or drug abuse within the last 12 months\n11. Prostate Specific Antigen (PSA) greater than 20ng\u002Fml\n12. Use of suprapubic catheterization after failed urethral catheterization\n13. Neurogenic bladder dysfunction, confirmed or suspected, irrespective of etiology\n14. Isolated bladder neck disease\n15. Acute or chronic prostatitis\n16. Confirmed or suspected urethral stricture\n17. Known bladder stones\n18. Use of the following medications prior to and during study participation:\n\n    1. Any other IMP (within 3 months of enrolment)\n    2. Herbal medications known to have anti-androgenic effects (e.g. red reishi, licorice, white peony, green tea, spearmint, black cohosh, chaste tree, saw palmetto, etc) (within 3 months of enrolment)\n    3. Anti-androgen therapy (within 3 months of enrolment)\n    4. T replacement therapy (within 3 months of enrolment)\n    5. 5α-reductase inhibitor treatment etc. (within 25 weeks prior to screening: dutasteride; within 12 weeks prior to screening: finasteride (and others))\n    6. Bethanechol chloride\n    7. Any other medication or herbal product that may affect hormone levels and might, therefore, confound interpretation of the study results (e.g. St. John's wort) (within 3 months of enrolment)","MALE","45 Years",{"count":19,"type":20},126,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk of recurrent urinary retention and subsequent surgical or minimally invasive intervention.\n\nThe study is designed to evaluate the effects of Teverelix DP on total prostate volume and urinary function and to prospectively evaluate clinically meaningful outcomes including recurrent AUR, BPH-related surgical or minimally invasive intervention, protocol-defined treatment failure and clinical benefit.\n\nParticipants will be randomized to one of four treatment groups evaluating two active Teverelix DP regimens: 90 mg administered intramuscularly (IM) and 120 mg administered subcutaneously (SC) and their respective matched placebo controls.\n\nThe primary endpoint is percent change from baseline in total prostate volume (TPV) at Week 12. Participants will continue to be evaluated during the 28-week treatment period for urinary function and prospectively defined clinical outcomes, including recurrent AUR, BPH-related intervention, treatment failure and clinical benefit, and will be followed through Week 52 for protocol-defined longer-term assessments and safety follow-up.\n\nThe study is designed to characterize biological activity, urinary function, clinical outcomes, safety and the relative treatment effects of the two Teverelix DP regimens to inform dose and route selection and subsequent clinical development.",[26,27],"Acute Urinary Retention","Benign Prostate Hypertrophy(BPH)",[29,30,31,32,33,34],"Prostatic Diseases","Teverelix","Acute urinary retention","Benign Prostate Hypertrophy","AUR","BPH","NOT_YET_RECRUITING","2026-07-27",{"date":38,"type":39},"2026-07-29","ACTUAL",{"date":41,"type":20},"2026-09",{"date":43,"type":20},"2028-05",{"name":45,"class":46},"Antev Ltd.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100641769","phase-4-tamsulosin-with-or-without-tadalafil-for-trial-without-catheter-after-acute-urinary-retention-due-to-benign-prostatic-hyperplasia-100641769","NCT07654413","Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia","Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial","TAMS-TAD-TWOC","Inclusion Criteria:\n\n* Male patient aged 50 years or older.\n* First episode of spontaneous painful acute urinary retention.\n* Successful urethral catheterization at presentation.\n* Drained urine volume at presentation of at least 300 mL.\n* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and\u002For ultrasound evidence of enlarged prostate.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous episode of acute urinary retention.\n* Chronic painless urinary retention phenotype.\n* Active urinary tract infection or sepsis.\n* Gross hematuria with clot retention.\n* Suspected or known urethral stricture.\n* Neurogenic bladder or major neurologic disease affecting voiding.\n* History of prostate cancer or bladder cancer.\n* Previous prostate surgery.\n* Current use of nitrates or guanylate cyclase stimulators.\n* Contraindication to tadalafil or tamsulosin.\n* Severe hypotension or unstable cardiovascular disease.\n* Severe renal impairment.\n* Severe hepatic impairment.\n* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.","50 Years",{"count":57,"type":20},320,[59],"PHASE4","Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization.\n\nThis study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia.\n\nParticipants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14.\n\nThe main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.",[26,62,63],"Benign Prostatic Hyperplasia","Benign Prostatic Obstruction",[65,66,67,68,62],"Trial Without Catheter","TWOC","Tamsulosin","Tadalafil","RECRUITING","2026-06-12",{"date":72,"type":39},"2026-06-17",{"date":74,"type":39},"2026-06-08",{"date":76,"type":20},"2027-12",{"name":78,"class":79},"Beni-Suef University","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":80},"100642454","phase-4-tamsulosin-dose-escalation-or-silodosin-switch-before-trial-without-catheter-in-bph-related-acute-urinary-retention-100642454","NCT07650968","Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention","Tamsulosin 0.4 mg Continuation Versus Dose Escalation to 0.8 mg Versus Switch to Silodosin 8 mg for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Acute urinary retention requiring urethral catheterization.\n* Presumed acute urinary retention secondary to benign prostatic enlargement or benign prostatic obstruction.\n* Already receiving tamsulosin 0.4 mg once daily for at least 4 weeks before the acute urinary retention episode.\n* Successful urethral catheterization at presentation.\n* Initial catheterized urine volume ≤1000 mL, with a clinical presentation consistent with painful acute urinary retention.\n* Prostate enlargement on ultrasound or clinical assessment consistent with benign prostatic hyperplasia or benign prostatic obstruction.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected prostate cancer.\n* Previous prostate surgery.\n* Previous urethral stricture disease or urethral surgery.\n* Neurogenic bladder or known neurological disease affecting voiding.\n* Chronic urinary retention rather than acute painful retention.\n* Acute urinary retention due to non-BPH causes, including clot retention, bladder stone obstruction, acute prostatitis, urethral trauma, or drug-induced retention.\n* Severe urinary tract infection, sepsis, or fever at presentation.\n* Gross hematuria requiring irrigation.\n* Failed urethral catheterization or need for suprapubic catheterization.\n* Current use of silodosin, alfuzosin, doxazosin, terazosin, tadalafil, anticholinergics, beta-3 agonists, or other drugs that may significantly affect voiding.\n* Severe renal impairment requiring urgent intervention.\n* Symptomatic postural hypotension or recurrent syncope.\n* Known hypersensitivity to silodosin.\n* Severe hepatic impairment.\n* Inability to comply with follow-up.",{"count":89,"type":20},378,[59],"This randomized controlled trial will compare three medication strategies before trial without catheter in men with acute urinary retention due to benign prostatic hyperplasia who were already taking tamsulosin 0.4 mg once daily before the retention episode. After urethral catheterization, eligible participants will be randomly assigned to one of three groups for 7 days: continuation of tamsulosin 0.4 mg once daily, escalation to tamsulosin 0.8 mg once daily, or switching to silodosin 8 mg once daily. The urethral catheter will be removed on Day 7, and the ability to void successfully without re-catheterization will be assessed. Follow-up will continue to Day 30, with additional recording of catheter-free status, recurrent urinary retention, urinary flow, post-void residual urine, symptom scores, adverse drug events, catheter-related complications, and the need for later benign prostatic hyperplasia-related surgery.",[26,62],[65,67,94,95],"Silodosin","Catheter-free status","2026-06-11",{"date":98,"type":39},"2026-06-16",{"date":74,"type":39},{"date":101,"type":20},"2027-06",{"name":78,"class":79},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":80},"100614232","phase-4-perioperative-tamsulosin-for-treating-voiding-dysfunction-following-prostate-biopsy-100614232","NCT07276919","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy: A Multicenter, Randomized, Controlled, Open-Label Study","Inclusion Criteria:\n\n* Male, aged 40 to 85 years (inclusive).\n* Meets indications for prostate biopsy per clinical guidelines (e.g., suspicious nodule on digital rectal exam, suspicious lesion on imaging, tPSA \\>10 ng\u002FmL, or tPSA 4-10 ng\u002FmL with f\u002Ft \\\u003C0.16 or PSAD \\>0.15).\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Previous prostate surgery, urinary diversion, or intermittent catheterization.\n* Use of alpha-adrenergic blockers (e.g., Tamsulosin, Doxazosin) within one week prior to screening.\n* Known or suspected allergy\u002Fintolerance to Tamsulosin, or history of orthostatic hypotension.\n* Indwelling urinary catheter or suprapubic cystostomy tube at the time of biopsy.\n* History of severe bleeding disorders.\n* Poorly controlled or unstable comorbidities such as hypertension or diabetes.\n* Severe immunosuppression.\n* Severe psychological disorders or uncooperative for the biopsy procedure.\n* Active urinary tract infection or neurogenic bladder.\n* Any other condition deemed by the investigator as unsuitable for participation.","40 Years","85 Years",{"count":113,"type":20},1844,[59],"The goal of this clinical trial is to learn if the drug Tamsulosin Hydrochloride works to treat urination difficulties after a prostate biopsy in men.The main questions it aims to answer are:\n\n* Does Tamsulosin Hydrochloride lower the rate of Acute Urinary Retention (inability to urinate) after a prostate biopsy?\n* Does Tamsulosin Hydrochloride improve participants' urination symptoms, quality of life, urine flow rate, and post-void residual urine volume?\n\nResearchers will compare the drug group to a control group (receiving no preventive medication) to see if Tamsulosin Hydrochloride works to prevent urination problems.\n\nParticipants will:\n\n* Be randomly assigned to either take Tamsulosin Hydrochloride or receive no preventive medication.\n* If in the drug group, take one capsule of Tamsulosin Hydrochloride every night, starting 3 days before the biopsy and continuing until 6 days after the biopsy (10 doses total).\n* Undergo a standard prostate biopsy procedure (either through the rectum or perineum).\n* Return to the clinic 7 days after the biopsy for a follow-up checkup, which will include questions about their symptoms (IPSS and QoL scores) and tests to measure urine flow and bladder emptying.",[26,117],"LUTS(Lower Urinary Tract Symptoms)",[119,120,121,122],"acute urinary retention","LUTS(Lower urinary tract symptoms)","tamsulosin","prostate biopsy","2025-12-20",{"date":125,"type":39},"2025-12-23",{"date":127,"type":20},"2026-02-01",{"date":129,"type":20},"2028-01-01",{"name":131,"class":79},"Peking University First Hospital",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100614737","early-versus-delayed-trial-without-catheter-in-men-with-acute-urinary-retention-100614737","NCT07283484","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention.","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention: a Randomized Controlled Trial (the RELIEF Study).","RELIEF","Inclusion Criteria:\n\n* Adult men (≥18 years)\n* Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin)\n* Mentally competent and able to understand the potential benefits and burdens of study participation\n* Provision of written or digital informed consent\n\nExclusion Criteria:\n\n* Failed prior TWOC within the preceding 30 days\n* Initial urinary retention volume \\>1500 mL\n* Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida)\n* History of prostate cancer with ISUP grade group ≥2\n* History of active bladder cancer or ongoing surveillance for bladder cancer\n* Urinary retention occurring within 72 hours after surgery (postoperative urinary retention)\n* History of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, or prostate surgery)\n* AUR suspected to be caused by bladder stones\n* Suspected urethral stricture, clot retention, or urosepsis\n* Contraindication to alpha-blocker therapy","18 Years",{"count":142,"type":20},478,[144],"NA","Acute urinary retention (AUR) is a sudden and painful condition. It occurs when a person is unable to urinate. In men, AUR is most often caused by an enlarged prostate, known as benign prostatic hyperplasia (BPH), which blocks the urethra. The first steps in treatment are to insert a catheter to empty the bladder and to start medication that acts on the prostate (an alpha-blocker). After some time, the catheter is removed during a so-called \"Trial Without Catheter\" (TWOC) to see whether the patient can urinate normally again.\n\nAt present, it is unclear how long a catheter should remain in place before this trial is performed. In Dutch hospitals, the duration varies widely: in some hospitals, the catheter is removed after only a few days, while in others it stays in place for two weeks or longer. A longer catheter duration can cause more discomfort and complications, such as urinary tract infections or blood in the urine. Therefore, it is important to determine whether a shorter catheterization period is equally effective and safe compared to a longer one.\n\nThe RELIEF study investigates whether a short catheter duration of three days is as safe and effective as the current average of fourteen days. A total of 478 men with acute urinary retention will participate in this nationwide randomized controlled trial. All participants will receive a catheter and start (or continue) treatment with an alpha-blocker. They will then be randomly assigned to one of two groups: one group will have the catheter removed after three days, and the other group after fourteen days.\n\nThe main question is whether a shorter catheter duration is as successful as a longer one. Success means that the patient can urinate normally after catheter removal, without needing to have the catheter replaced. The study will also compare the number of complications, patients' experiences with the catheter, their quality of life, and the overall healthcare costs.\n\nBy conducting this study, doctors will gain better evidence on the optimal timing of catheter removal in men with AUR. The goal is to avoid unnecessarily long catheterization, reduce discomfort and complications, and improve the quality of care for men with AUR. The results of the RELIEF study may help improve the management of AUR, making care more consistent, efficient, and patient-friendly both in the Netherlands and abroad.",[26,147,148,27],"Benign Prostate Obstruction","Benign Prostate Hyperplasia",[138,26,150,66,65,151,152,153,154,155,156,157,34],"Urinary Retention","bladder catheter","urinary catheter","catheter removal","catheter withdrawal","Benign prostate obstruction","BPO","Benign prostate hyperplasia","2025-12-15",{"date":160,"type":39},"2025-12-22",{"date":162,"type":39},"2025-08-21",{"date":164,"type":20},"2029-03-01",{"name":166,"class":79},"Liselot Ribbert",11]